Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.45 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.45 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.45 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5504740 | 0.84 | KDM4E (0.54) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL6976863 | 0.84 | KDM4E (0.53) | KDM4EALDH1A1CA1CA2L3MBTL1 | |
| SCHEMBL25004248 | 0.84 | GFER (0.46) | KDM4ECA12CA1CA2TAAR1 | |
| SCHEMBL16034258 | 0.84 | KDM4E (0.61) | KDM4EALDH1A1CA1CA2HPGD | |
| SCHEMBL4452224 | 0.82 | IDO1 (0.54) | CA12CA1CA2CA4L3MBTL1 | |
| SCHEMBL4344215 | 0.81 | TAAR1 (0.54) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL3705685 | 0.81 | SCN3A (0.55) | KDM4EALDH1A1DPP4 | |
| SCHEMBL69319 | 0.79 | TAAR1 (0.52) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL5224472 | 0.79 | TAAR1 (0.57) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL4459745 | 0.78 | SMN1; SMN2 (0.59) | KDM4EALDH1A1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298781-A1 | COMPOUNDS FOR THE INHIBITION OF APOPTOSIS | CONSEJO SUPERIOR DE (ES) | 2009-12-03 | — | — | US | disclosed |
| EP-2045251-A1 | COMPOUND THAT CAN INHIBIT UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USES | Consejo Superior de Investigaciones Cientificas (ES) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298781-A1 | COMPOUNDS FOR THE INHIBITION OF APOPTOSIS | BAX, BCL2, CASP3 | KDM4E 3944/4885ALDH1A1 1468/4885CA12 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.